Ipsen (OTCMKTS: IPSEY) is one of 24 public companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Ipsen to related companies based on the strength of its valuation, profitability, earnings, institutional ownership, risk, analyst recommendations and dividends.
Institutional & Insider Ownership
0.0% of Ipsen shares are held by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are held by institutional investors. 13.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings and price targets for Ipsen and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given Ipsen’s peers higher possible upside, analysts plainly believe Ipsen has less favorable growth aspects than its peers.
Volatility & Risk
Ipsen has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, Ipsen’s peers have a beta of 1.44, suggesting that their average share price is 44% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ipsen and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ipsen||$2.27 billion||$408.99 million||41.28|
|Ipsen Competitors||$308.35 million||$18.66 million||-39.62|
Ipsen has higher revenue and earnings than its peers. Ipsen is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Ipsen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ipsen pays an annual dividend of $0.17 per share and has a dividend yield of 0.4%. Ipsen pays out 18.3% of its earnings in the form of a dividend. As a group, “Diagnostic substances” companies pay a dividend yield of 1.3% and pay out 41.9% of their earnings in the form of a dividend.
Ipsen beats its peers on 9 of the 15 factors compared.
Ipsen Company Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer. The company also provides Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Cometriq for medullary thyroid cancer; Dysport for motor disorders and muscular spasticity; NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, VSN16R, OPS201, and OPS202 drugs, as well as botulinum toxin. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.